natgillin/translations-raw huggingface dataset:
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6 alkyl, halogen and CF3; wherein 
Q je izabrani iz grupe koju čini fenil, piridil, tiazolil, tiofenil, pirimidil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabran iz grupe koju čini Cig alkil, halogen i CF3; gdje
A process for the preparation of a compound of Formula V and salts thereof comprising 
Postupak za dobivanje spoja s formulom V i njegovih soli HR P20171528 T1
The method of claim 1, wherein the group -C(=O)X is a carboxylic acid, and the compound of formula (I) is eicosapentaenoic acid (EPA). 
Postupak prema zahtjevu 1, naznačen time da skupina -C(=0)X je karboksilna kiselina, a spoj s formulom (I) je eikozapentaenska kiselina (EPA).
to have an increased effector function as compared to the non-glycoengineered antibody, wherein the increased effector function is an increased direct signaling induction of apoptosis. 
(iv) kako bi imalo povećanu efektorsku funkciju u usporedbi prema protutijelu koje nije bilo podvrgnuto glikoinženjeringu, gdje je povećana efektorska funkcija zapravo povećana izravna signalna indukcija apoptoze.
An immunoconjugate according to any one of claims 7 to 13 wherein the antibody comprises a heavy chain consisting of sequence SEQ ID NO:87 and a light chain consisting of sequence SEQ ID NO:88 and is covalently linked via N-succinimidyl pyridyldithiobutyrate (SPDB) to N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4). 
Imunokonjugat prema bilo kojem od zahtjeva 22 do 28, naznačen time da protutijelo sadrži teški lanac koji sadrži sekvencu SEQ ID NO:87 ili sekvencu koja je s njom barem 85% identična i laki lanac koji sadrži sekvencu SEQ ID NO:88 ili sekvencu koja je s njom barem 85% identična.
The formulation of paragraph 1 wherein the insulin is provided in a dry powder in a first container and at least one of the chelator and dissolution agent are provided in a second container containing a diluent. 
Formulacija prema zahtjevu 1, naznačena time da je inzulin osiguran u obliku suhog praha u prvom spremniku i najmanje jedan kelator cinka i sredstvo za rastvaranje su osigurani u drugom spremniku koji sadrži otapalo.
Multi-purpose truck (100) for re-establishment of safe and practicable road conditions, after car accidents, through cleaning of the road platform, according to one or more of previous claims, characterized in that further comprising: 
Višenamjenski kamion (100) za ponovno uspostavljanje sigurnih i prohodnih uvjeta na cesti nakon automobilskih nezgoda, čišćenjem cestovne plohe, prema jednom ili više prethodnih patentnih zahtjeva, naznačen time, da nadalje sadrži:
The composition of claim 1, wherein the sorbitol and natural gum are in a weight ratio of at least 1.4:1. 
Kompozicija prema bilo kojem od zahtjeva 1-3, pri čemu su sorbitol i prirodna guma u težinskom odnosu najmanje od 14:1.
from a compound of the Formula VII: 
Br iz spoja sa formulom VII: 5
The polyalkylene oxide-adenosine deaminase conjugate of claim 6, wherein the polyalkylene oxide is polyethylene glycol. 
Konjugat adenozin deaminaze i polialkilen oksida u skladu s patentnim zahtjevom 6, naznačen time, da je polialkilen oksid polietilen glikol.
An optically pure diastereoisomeric salt of formula (II): 
Optički čista dijastereoizomerna sol formulo (IT): o
Feeding of elementary selenium vapor into the processing chamber from a substrate temperature ranging from 100° C. to 350° C., in particular between 120° C. and 300° C., if appropriate, followed by the feeding of elementary sulphur vapor into the processing chamber, and here if appropriate, the subsequent adjustment of the selenium source temperature to a required partial pressure, preferably between 0.001 mbar and 100 mbar 
- < dovođenja para elementarnog selenija u radnu komom od temperature supstrata između 120% 1 300%, uz podešavanje temperature izvora selenija do željenog parcijalnog tlaka, po mogučnosti između 0,001 mbar (0,1 Pa) i 100 mbar (10 kPa);
The compound or salt for use according to claim 9, wherein said additional pharmaceutical agent is selected from melphalan plus prednisone, doxorubicin, dexamethasone, and bortezomib. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 24, naznačen time da je dodatno farmaceutsko sredstvo izabrano od melfalana, melfalana plus prednizona, doksolrubicina, deksametazona, i bortezomiba.
Wind system according to claim 5, characterised in that around each of said first winches (24) said rope (4) is wound for three quarters of circumference. 
Vjetreni sustav prema zahtjevu 5, naznačen time da se oko svakog od spomenutih prvih vitala (24) spomenuto uže (4) namotano na tri četvrtine opsega.
shaking a suspension containing crystalline modification A and/or crystalline modification B of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and 
(a) protresanje suspenzije koja sadrži kristalnu modifikaciju A i/ili kristalnu modifikaciju B (1R,2R)-3-(3- dimetilamino-1 -etil-2-metilpropil)fenola, pri čemu je suspenzijski medij metanol ili toluen, i
coating the core using at least one coating preparation selected from the group consisting of an isolation layer coating preparation comprising a non-ionic polymer that is soluble in intestinal fluid or gastrointestinal fluid, in a solvent system, and an inner layer coating preparation comprising a third polymeric material that is a non-ionic polymer which is soluble in intestinal fluid or gastrointestinal fluid, in a solvent system, to form an intermediate coated core and; combining an aqueous preparation of a first polymeric material which is susceptible to attack by colonic bacteria with an organic preparation of a second polymeric material which has a pH threshold of pH 6 or above, to form an outer layer coating preparation coating the intermediate coated core with the outer layer coating preparation to form an outer layer coated core, 
oblaganje jezgre upotrebom unutarnjeg preparata za oblaganje sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, u sustavu otapala da se formira unutrašnje obložena jezgra; i oblaganje unutarnje obložene jezgre s vanjskim premaznim pripravkom sadrži prvi polimerni materijal koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima pH granicu od pH 6,5 ili više u sustavu otapala, da se dobije vanjska obložena jezgra; pri čemu je spomenuti treći polimerni materijal je polimer polikarboksilne kiseline koji je barem djelimično neutraliziran, pri čemu najmanje 10% skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku aniona karboksilata.
A compound of the formula: or a pharmaceutically acceptable salt thereof. 
biološki uzorak efikasne količine spoja formule: ili njegove farmaceutski prihvatljive soli.
C is a functional group that forms a bond with the 5'-end of Y; 
C je funkcionalna grupa prilagođena tako da se veže s 3’-krajem oligonukleotida;
A monoclonal antibody or functional part thereof according to claim 1 or 2 or a composition according to claim 4 or a mixture according to any one of claims 5 to 7 for use in: reducing the plaque load in the brain of an animal suffering from a disease or condition leading to an increased plaque load in the brain; 
Sastav prema zahtjevu 10 ili 11, za primjenu u: smanjenju tereta plakova (pločica) ili smanjenju količine plakova u mozgu neke životinje, posebno sisavaca, ali naročito humanog bića koje pati od bolesti ili bolesnog stanja asociranih sa amiloidom; ili
The data sheet thus includes a data portion 3 made of uniform plastic material. 
List za podatke na taj način uključuje predio za podatke 3 koji je načinjen od jednoličnog plastičnog materijala.
The pharmaceutical composition according to claim 4, wherein the one or more additional antibodies or radioimmunoconjugates are specific for CD20. 
Farmaceutska kompozicija u skladu sa zahtjevom 4, naznačena time što jedno ili više antitijela ili radioimunokonjugata djeluju protiv CD20.
ESD association standard (ANSI/ESDS7.1-1994)) 
2) Standard udruge ESD (ANSI/ESDS7.1 -1994)
and R2 represent independently hydrogen, or C1-6 alkyl, with straight or branched chain and optionally substituted with one or more C1-6 alkoxycarbonyl, phenyl or (C1-6 alkoxycarbonyl)-C1-6 alkyl group or R1 and R2 may form a heterocyclic ring with the adjacent nitrogen atom, which may be saturated optionally by C1-6 alkyl or hydroxy substituted monocyclic ring, which may contain further heteroatoms selected from O or N, or 
R; i R» mogu tvoriti heterociklički prsten sa susjednim atomom dušika, koji može biti zasićen opcijski s Cy.4 alkilom ili hidroksi supstituiranim monocikličkim prstenom, koji može nadalje sadržavati heteroatome odabrane od O1li N, ili C2.7 alkenil s jednom dvostrukom vezom, ili fenil ili naftil skupina opcijski supstituirana s jednom ili više od sljedećih skupina: C,.4 alkoksi, trifluoro-C1.4 alkoksi, Cig alkoksikarbonil, Cig alkanoil, aril, C;.4 alkiltio, halogen ili cijano, ili cikloheksil ili adamantil skupina, ili benzoil skupina;
The siRNA according to the aforementioned 1) to 4), wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3′ terminus of the sense strand of the siRNA are converted into DNA and 1 to 10 consecutive nucleotides from the 5′ terminus of the antisense strand of the siRNA are converted into DNA. 
SIRNA u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da se 1 do 10 uzastopnih nukleotida s iznimkom izbočenog nukleotida iz 3' terminusa sens lanca siRNA pretvaraju u DNA 1 da se 1 do 10 uzastopnih nukleotida iz 5' terminusa antisens lanca siRNA pretvaraju u DNA.
a water-soluble flavouring agent; and/or 
sredstvo za poboljšanje okusa topljivo u vodi; i/ili
The complex or pharmaceutical composition for use according to embodiment 8, wherein the treatment comprises parenterally administering said complex of embodiment 5 or pharmaceutical composition of embodiment 6. 
Kompleksni spoj ili farmaceutski spoj za uporabu u skladu s patentnim zahtjevom 8, pri čemu liječenje sadrži parenteralnu primjenu navedenog kompleksnog spoja u skladu s patentnim zahtjevom 5 ili farmaceutski spoj u skladu s patentnim zahtjevom 6.
B1, B2 and B3 are independently CR2 or N; 
, B2 i B3 su neovisno odabrani iz skupine koja se sastoji od CR2 i N;
The method of claim 13, wherein said polymer is selected from homopolymers of acrylic acid crosslinked with polyalkenyl polyether, polyoxyethylene-polyoxypropylene block copolymers, cellulose or acrylic derivatives, alginates, collagen, hyaluronic acid or its derivatives, and chitosan or its derivatives. 
Upotreba u skladu s patentnim zahtjevom 16, gdje se navedeni polimer bira između homopolimera akrilne kiseline, umreženih s polialkenil-polieterom, polioksietilen-polioksipropilenskim blok-kopolimerom, derivatima celuloze ili akrilne kiseline, alginatima, kolagenom, hijaluronskom kiselinom ili njenim derivatima, kitozanom ili njegovim derivatima, 18.
In some embodiments, the method of screening includes the steps of inducing in a doubly humanized rodent as described herein a disease associated with IL-4/IL-4Ra signaling, administering an agent to the rodent, determining whether the agent ameliorates the disease, and identifying the agent as a human-specific IL-4 or IL-4Ra antagonist suitable for treating the disease if the agent ameliorates the disease. 
Postupak probira na ljudsko specifični antagonist IL-4 ili IL-4Ra, naznačen time što se sastoji u: osiguravanja dvostruko humaniziranog IL-4 i IL-4Ra. glodavca u skladu s patentnim zahtjevom 6, izazivanja plućne upale kod navedenog glodavca, primjene sredstva na navedenom glodavcu, određivanja smanjuje li sredstvo plućnu upalu, te identificiranja sredstva kao ljudsko specifičnog antagonista
Installation according to claim 1, characterized in that the external lateral surface of the outer rotor (1) is provided with circular heat exchange fins (23), in that internal surface of the outer cylinder(1) is provided with heat exchange fins (21) which are perpendicular to its surface and parallel to its axis and converge toward the rotation axis. 
Sistem iz patentnog zahtjeva 1, u okviru kojega su na bočnoj vanjskoj površini vanjskog cilindra (1) postavljena kružna rebra za razmjenu topline (23), dok se duž unutranje površine vanjskog cilindra (1) nalaze rebra za razmjenu topline (21) koja su postavljena uspravno na površinu vanjskog cilindra i paralelno njegovoj osi simetrije, konvergirajući prema osi rotacije cilindra,
This portion is extracted with DCM (2×3 ml) and the organic extracts are combined and concentrated in vacuo to yield the titled compound as a white solid. 
Taj dio se ekstrahira s DCM-om (2 x 3 ml) i organski ekstrakti se sjedine i koncentriraju u vakuumu, čime se dobije naslovni spoj kao bijela kruta tvar.
A pharmaceutical composition comprising a tumour associated peptide according to any one of Claims 1 to 3, a nucleic acid according to Claim 5 or an expression vector according to Claim 6 and a pharmaceutically acceptable carrier, preferably in the form of a cancer vaccine, optionally comprising at least one suitable adjuvant. 
Farmaceutski sastav koji obuhvaća tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 te Tarmaceutski prikladan nosač, poželjno u obliku cjepiva protiv raka, a po izboru može sadržavati barem jedan prikladan adjuvans.
contacting the antigen presenting cell of step (iii) with a T cell to evaluate the ability of the peptide to stimulate the T cell; and 
(iv) stavljanja u kontakt stanice za predočavanje antigena iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da simulira T-stanicu; 1
A 1:1-mixture of acetonitrile:water is used as an eluent for the chromatography. 
Kao sredstvo za kromatografiju upotrebljava se mješavinu 1:1 acetonitrila i vode.
sequentially dosing each of the liquefied gel compositions into a container. 
(vi) uzastopnog doziranja svakog od likveficiranih želiranih pripravaka u spremnik.
At this point, it is possible to move to the stem and provide a short command to reverse the engines in order to tie the stern to the dock, with the assistance of persons on the dock, or with the assistance of a member of the crew. 
U ovom trenutku, moguće je prijeći na krmu i dati kratku komandu reverziranja motora, kako bi se privezala krma uz pristanište, uz pomoć osoba na pristaništu, ili uz pomoć člana posade.
An in vitro method of inducing a cytotoxic T cell by contacting a T cell with a peptide of any one of claims 1 to 7. 
Postupak induciranja stanice za predočavanje antigena koja može inducirati citotoksičnu T-stanicu in vitro, naznačen time što se sastoji u koraku:
For oral administration, the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 200, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. 
Za oralno davanje pripravci se poželjno daju u obliku tableta koje sadržavaju 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 50.0, 100, 200, te 500 miligrama aktivnog sastojka, za simptomasko podešavanje pacijentu koji se liječi.
A method of analyzing a biological sample of an organism, the biological sample including DNA fragments originating from normal cells and potentially from cells associated with cancer, wherein at least some of the DNA fragments are cell-free in the biological sample, the method comprising: 
Metoda za analizu uzorka materinske plazme uzetog od trudnice, pri čemu uzorak sadrži fragmente izvanstanične DNK koji potječu iz materinskih stanica i fetalnih stanica, pri čemu se metoda sastoji od:
Abiraterone acetate for use in a method of treatment of a prostate cancer in a human, wherein the abiraterone acetate is administered in an amount of 50 mg/day to 2000 mg/day, and wherein the abiraterone acetate is to be administered in addition to 10 mg/day to 250 mg/day of prednisone. 
Abirateron acetat za upotrebu u postupku tretmana raka prostate kod ljudi, naznačen time, što se abirateron acetat primjenjuje u količini od 50 mg/dan do 2000 mg/dan, i naznačen time, što se abirateron acetat primjenjuje u kombinaciji sa dozom prednizona od 10 mg/dan do 250 mg/dan.
provided that, when Ar1 is A1a), combinations of the substituents R6, R7 and R8 exclude a combination of a hydrogen atom and a halogen atom. 
tako da, kada Ar1 je A1a), kombinacije supstituenata R6, R7 i R8 isključuju kombinaciju atoma vodika i halogenog atoma.
The process of any of claims 1-8, wherein the antibody is selected from the group consisting of huN901, huMy9-6, huB4, huC242, trastuzumab, bivatuzumab, sibrotuzumab, CNT095, huDS6, and rituximab. 
Postupak prema patentnom zahtjevu 8, naznačen time što je antitijelo izabrano iz grupe koju čine huN901, huMy96, huB4, huC242, trastuzumab, bivatuzumab, sibrotuzumab, CNTO95, huDS6 i rituksimab.
A compound as claimed in claim 1 or a physiologically functional derivative thereof selected from pharmaceutically acceptable esters, amides and carbamates, salts and solvates thereof wherein E represents heteroaryl substituted by one or more C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, cyano, hydroxy, nitro, amino, -N(CH3)2, -NHCOC1-6, alkyl, - OCF3, -CF3, -COOC1-6 alkyl, -OCHCF2, -SCF3, -CONR5R6, -SO2N(CH3)2, -SO2CH3 or - SCH3 groups, or by fused cycloalkyl or heterocyclic rings which may themselves be substituted, for example by carbonyl groups. 
HR P20080668 T3 Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, gdje E predstavlja heteroaril supstituiran s jednim ili više Ci.4 alkilnih, C2.g alkenilnih, halogenih, C,_g alkoksi, cijano, hidroksi, nitro, amino, -N(CH;),, -NHCOC, 4 alkilnih, -OCF.;, -CF3, -COOC, 4 alkilnih, -OCHCEF,, -SCF., -CONR"R", -SO>;N(CH3),, -SO2CH; ili -SCH; skupina, ili s kondenziranim cikloalkilnim ili heterocikličkim prstenima, koji 1 sami mogu biti supstituirani, primjerice s karbonilnim skupinama.
The packaging and the device for manual rolling of cigarettes as claimed in Claim 5, characterized in that variously shaped clamps may be arranged instead of the lugs (6g') and the openings (6a'). 
Pakiranje i uređaj za ručno motanje cigareta, prema zahtjevu 5, naznačen/o time, da umjesto uha (6g') i otvora (6a), mogu se rasporediti spone različitih oblika.
Since the film forming agent may be used with a wide variety of solvents, the formulation can be chosen in a way that the nail topical formulation composition in accordance with the present invention does not burn nor cause irritation and is easily removable without the use of organic solvents. 
S obzirom da se agens koji tvori film može koristiti s brojnim različitim otapalima, formulacija se može odabrati tako da pripravak za topikalnu primjenu na noktima, u skladu s ovim izumom, ne peče ili uzrokuje iritaciju i da se lako uklanja bez upotrebe organskih otapala.
The soft chewable veterinary composition of claim 7, wherein the humectant is glycerin, propylene glycol, cetyl alcohol or glycerol monostearate, more preferably, glycerin. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 7, naznačen time, da ovlaživač je glicerin, propilenglikol, cetilni alkohol ili glicerol-monostearat, još poželjnije glicerin.
is aminopyridyl, in which aminopyridyl is unsubstituted or substituted independently of one another once, twice or three times by halogen or methyl, Y is -(C3-C8)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, or the radical of the formula III -A3-A5 (III) wherein 
je aminopiridil, gdje aminopiridil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran halogenom ili metilom, Y je -(C3-C8)-cikloalkil, gdje cikloalkil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s R1, ili radikal formule III A3-A5 (III), gdje
a sun exposure filter and mirroring circuit (103) extracting a sun exposure signal (S3) from the analog electrical signal (S1), 
filtera izloženosti suncu i zrcalnog kruga (103) koji izvlače signal izloženosti suncu (S3) iz analognog električnog signala (S1),
The method according to statement 1 or 2, wherein the sealing comprises heat sealing, preferably wherein the sealing is heat sealing. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da brtvljenje podrazumijeva toplinsko brtvljenje, poželjno je da je brtvljenje toplinsko brtvljenje.
a heavy chain variable domain having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO:208 and a light chain variable domain having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO:207; or comprising HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein: 
varijabilnu domenu jakog lanca koja sadrži HVR1-H1, HVR-H2 i HVR-H3 od SEQ ID NO:183-185 i varijabilnu domenu slabog lanca koja sadrži HVR-L1, HVR-L2 i HVR-L3 od SEQ ID NO:175-177; ili
by fractional crystallization of d- or 1-(tartrates, mandelates or camphorsulphonate) salts. 
frakcionom kristalizacijom d- ili t- soli (tartarata, mandelata ili kamforosulfonata).
Aspect 17. A method of treating a subject suffering from or susceptible to a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer, comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising: 
Sastav iz patentnog zahtjeva 5 ili 6, ili patentnih zahtjeva 7-10, gdje ovisno o patentnom zahtjevu 5 ili 6, nadalje obuhvaća drugi terapijski agens koristan u liječenju ili sprečavanju bolesti 1li stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih poremećaja; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
is filtered to remove the charcoal from the solution and is rinsed with water, and while keeping the internal vessel temperature below 5°C the pH of the reaction mixture is adjust to ≥ 8 with a diluted sodium hydroxide solution, and 
Cc) filtrira se da se iz otopine ukloni ugljen, te se ispire vodom, i d) uz održavanje unutarnje temperature posude ispod 5C pH reakcijske smjese se podešava na > 8 sa razrijeđenom otopinom natrijevog hidroksida, i